Bristol-Myers Squibb

Facing challenges in emergency medicine (Cardiff University)

Edit Public Technologies 13 May 2016

(Source. Cardiff University). Some of the world's leading experts in global emergency medicine will gather in Cardiff next week to discuss the challenges facing emergency departments and acute medical units ... 'The aging population, economic crisis and inefficiencies in healthcare are placing a huge burden on emergency and acute general medicine ... Platinum sponsors include Bristol-Myers Squibb, Pfizer, Galen, Shire, and Dot Medical Ltd....

Bavarian Nordic Announces Interim Results for the First Three Months of 2016 (Bavarian Nordic A/S)

Edit Public Technologies 13 May 2016

(Source. Bavarian Nordic A/S). COPENHAGEN, Denmark, May 13, 2016 - Bavarian Nordic A/S (OMX. BAVA, OTC. BVNRY) announced today its interim financial results for the first three months of 2016. Below is a summary of business progress and financial performance for the period ... Financial performance ... DKK million. USD million. 3m 2016. 3m 2015 ... 23 ... 4 ... The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC....

HTG Molecular Diagnostics Announces Immuno-Oncology Research Collaboration Agreement with Bristol-Myers Squibb (HTG Molecular Diagnostics Inc)

Edit Public Technologies 12 May 2016

The collaboration between HTG and Bristol-Myers Squibb will utilize the next generation sequencing (NGS)-based HTG EdgeSeq system as a tool for use in support of Bristol-Myers Squibb's translational research activities ... This collaboration is the result of a long-standing Bristol-Myers Squibb/HTG relationship and we are excited to continue as a ......

3SBio, Bristol-Myers Squibb - Research and Markets

Edit Business Wire 12 May 2016

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2016" report to their offering. The report provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type ... ....

Cancer institute receives $1.6M grant to battle lung cancer on the road

Edit Business Journal 12 May 2016

The Levine Cancer Institute’s efforts to promote early identification of lung cancer have received a $1.6 million boost thanks to a grant from Bristol-Myers Squibb Foundation. The Charlotte cancer institute, part of Carolinas HealthCare System, says those funds will be used to support the Lung B.A.S.E.S. 4 Life initiative ... “If you… ... ....

Supreme Court oral argument calendar for June 1 and 2, 2016 (Supreme Court of California)

Edit Public Technologies 12 May 2016

(Source. Supreme Court of California) 1 SUPREME COURT OF CALIFORNIA ORAL ARGUMENT CALENDAR LOS ANGELES SESSION. JUNE 1 and 2, 2016. FILED 05/12/2016 ... WEDNESDAY, JUNE 1, 2016 - 2.00 P.M. People v. Armstrong (Craigen Lewis) [Automatic Appeal], S130659. People v. Rinehart (Brandon Lance), S222620. People v ... Bristol-Myers Squibb Company v ... v ... (noodl....

HTG Molecular Diagnostics Reports First Quarter 2016 Results

Edit Stockhouse 12 May 2016

Entered into a multi-year Collaboration Agreement with Bristol-Myers Squibb (“BMS”) to evaluate immuno-oncology molecular profiling in multiple tumor types and support BMS’s translational research programs ... “We are very excited to have this immuno-oncology collaboration with Bristol-Myers Squibb....

HTG Molecular Diagnostics Reports First Quarter 2016 Results (HTG Molecular Diagnostics Inc)

Edit Public Technologies 12 May 2016

Entered into a multi-year Collaboration Agreement with Bristol-Myers Squibb ('BMS') to evaluate immuno-oncology molecular profiling in multiple tumor types and support BMS's translational research programs Secured distribution agreements with Gamidor Diagnostics (Israel) and Durvis s.l ... 'We are very excited to have this immuno-oncology collaboration with Bristol-Myers Squibb....

Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis (PVNS) (Five Prime Therapeutics Inc)

Edit Public Technologies 12 May 2016

(Source. Five Prime Therapeutics Inc). May 12, 2016. SOUTH SAN FRANCISCO, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc ... Five Prime initiated patient dosing in this Phase 1/2 clinical trial of FPA008 in July 2015 ... In January 2016, the U.S ... About PVNS ... About FPA008 ... FPA008 is being developed under an exclusive worldwide license and collaboration agreement with Bristol-Myers Squibb (BMS). About Five Prime ... CONTACT ... Source....

Gov't Forces Big Pharma to Swallow a Bitter Pill

Edit Caixin Online 12 May 2016

The authorities are changing market rules, making multinational drug companies adjust their business strategies. By staff reporter Li Yan ... Negotiations between the two sides, which started late last year, could reduce prices for these drugs by more than half, the commission says ... Bristol-Myers Squibb says it has cut its sales team by about 1,000 since July 2014, while Novartis said in November that it had eliminated 130 positions ... ....

European Commission Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo® (nivolumab) + Yervoy® ...

Edit Business Wire 11 May 2016

PRINCETON, N.J.--(BUSINESS WIRE)--$bmy #CheckMate--European Commission Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen, for Treatment of Advanced Melanoma ... ....